BioAro, an innovator in the fields of science, longevity and healthspan, announced the launch of its AI genomic analysis software at INVENTURES 2024 last week. The Calgary healthtech company’s software promises to significantly reduce healthcare wait times across Canada.
BioAro has been focused on advancing precision health strategies to enhance healthspan and longevity. Its mission focuses on the research, development, and implementation that can ensure accessible precision care for Canadians.
PanOmiQ, touted as the world’s fastest and most accurate disease-identification software, can diagnose and prevent life-threatening diseases swiftly and accurately. In just seven hours, the software can analyze vast amounts of data, generating a detailed report on a patient’s disease and genetic predispositions. This report is tailored to the patient’s medical history, leveraging the software’s AI-powered engine.
What sets PanOmiQ apart is its ability to process multiple samples simultaneously, a stark contrast to traditional genome processing which can take between two to four weeks. This remarkable speed could enable nationwide genomics programs.
At the launch, BioAro’s Founder and CEO, Dr. Anmol S. Kapoor, said, “PanOmiQ is an all-in-one solution for genetic analysis and report generation. It revolutionizes the world of genetic analysis. Our cutting-edge platform enables comprehensive analysis of diverse omic data types, including genomics, transcriptomics, proteomics, and metabolomics, all within a single, seamless interface.”
Cancer and heart disease are the leading causes of death in Canada, accounting for over 40% of all fatalities.
PanOmiQ aims to assist healthcare providers in addressing these critical health issues. By offering real-time clinical interpretation of significant heritable conditions, PanOmiQ empowers Canadians with timely insights for prevention and management. This leads to more effective treatment strategies, better patient outcomes, and the avoidance of unnecessary expenses associated with incorrect interventions and imprecise pharmaceutical care.
“With the launch of PanOmiQ, we are ushering in a new era of precision medicine, where every patient can receive tailored treatments based on their unique genetic makeup,” noted Kapoor.
BioAro’s innovative approach is positioning Canada as a frontrunner in biotechnology and personalized medicine, and paving the way for a healthier and more personalized future for all.
Leave a Reply